文献速递头颈与中枢神经肿瘤

顺铂药代动力学与头颈癌患者骨骼肌质量的关联:前瞻性PLATISMA研究

The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study.
PubMed 文献 · Eur J Cancer · 2021-11-19

该前瞻性观察研究纳入45例接受顺铂为基础放化疗的局部晚期头颈鳞癌患者,发现顺铂药代动力学与骨骼肌质量、体重、去脂体重及体表面积均存在显著关联(p<0.005),模拟显示低骨骼肌质量(<25.8 kg)患者预测达到更高顺铂浓度上限,但该关联同样见于其他体成分描述指标。

要点

  • 45例可评估患者中46.7%存在低骨骼肌质量,57.8%发生顺铂剂量限制性毒性。
  • 顺铂药代动力学与骨骼肌质量、体重、去脂体重及体表面积均显著相关(p<0.005)。
  • 模拟显示低骨骼肌质量(<25.8 kg)患者预测达到更高顺铂浓度上限。

核心结论

  • 研究发现顺铂药代动力学与骨骼肌质量存在关联,但该关联同样见于顺铂药代动力学与其他体成分描述指标之间。

研究设计与样本

  • 前瞻性观察研究,纳入45例接受标准治疗化疗(顺铂100 mg/m2每周期,共三周期)的局部晚期头颈鳞癌放化疗患者。
  • 通过CT扫描测量骨骼肌质量,收集顺铂药代动力学数据(总血浆浓度和超滤血浆浓度)及毒性数据。

主要发现

  • 45例可评估患者中,46.7%存在低骨骼肌质量。
  • 57.8%的患者发生顺铂剂量限制性毒性。
  • 药代动力学分析显示顺铂药代动力学与骨骼肌质量、体重、去脂体重及体表面积之间存在显著关联(p<0.005)。
  • 模拟显示低骨骼肌质量(<25.8 kg)患者预测达到更高顺铂浓度上限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Locally advanced head and neck squamous cell carcinoma (HNSCC) is commonly treated with cisplatin-based chemoradiotherapy (CRT). Cisplatin is associated with severe toxicity, which negatively affects survival. In recent years, a relationship between low skeletal muscle mass (SMM) and increased toxicity has been described. This increased toxicity may be related to altered cisplatin distribution and binding in the fat-free body mass of which SMM is the largest contributor. This study aims to investigate the association between cisplatin pharmacokinetics and SMM in patients with HNSCC. METHODS: We performed a prospective observational study in patients with HNSCC treated with CRT. Patients received standard-of-care chemotherapy with three cycles of cisplatin at a dose of 100 mg/m2 per cycle. Quantitative data on SMM, measured on computed tomography scans and cisplatin pharmacokinetics (total and ultrafilterable plasma concentrations) were collected, as well as data on toxicity. RESULTS: A total of 45 evaluable patients were included in the study. A large proportion of the study population had a low SMM (46.7%). The majority of patients (57.8%) experienced cisplatin dose-limiting toxicities. Pharmacokinetic analysis showed a significant relationship between cisplatin pharmacokinetics and SMM, weight, fat-free mass and body surface area (p < 0.005). In a simulation, patients with a low SMM (<25.8 kg) were predicted to reach higher-bound cisplatin concentrations. CONCLUSION: We found an association between cisplatin pharmacokinetics and SMM; however, this relationship was also seen between cisplatin pharmacokinetics and other body composition descriptors.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chargi N, Molenaar-Kuijsten L, Huiskamp LFJ, et al. The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study. Eur J Cancer. 2021. PMID: 34810046. doi:10.1016/j.ejca.2021.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。